---
aliases: [LLY, Lilly]
---
#actor #healthcare #pharma #usa #public #ai

**Eli Lilly** — Top pharma by market cap. GLP-1 leader (Mounjaro, Zepbound). [[AI drug discovery]] investments.

---

## Q4 2025 earnings (Feb 4, 2026)

**Blowout quarter. Stock soaring.**

| Metric | Actual | Expected |
|--------|--------|----------|
| Q4 Revenue | **$19.3B** | $18.0B |
| Q4 EPS | **$7.54** adj | $6.93 |
| YoY Revenue | **+43%** | — |
| 2026 EPS Guide | **$34.25** mid | $33.30 |

Mounjaro and Zepbound driving volume growth. CEO Ricks: "2025 was an important year for Lilly."

**Context:** While [[Novo Nordisk]] guided -5% to -13% sales decline, Lilly delivered +43% growth. GLP-1 market share divergence accelerating.

---

## Why Eli Lilly matters

| Metric | Value |
|--------|-------|
| Market cap | ~$750B |
| Ticker | LLY (NYSE) |
| Focus | GLP-1, oncology, immunology |
| AI angle | Drug discovery, clinical trials |

---

## AI in drug discovery

| Initiative | Description |
|------------|-------------|
| [[Isomorphic Labs]] | DeepMind spinoff partnership |
| In-house ML | [[Target]] identification, molecule design |
| Clinical trial AI | Patient selection, site optimization |

**Thesis:** AI accelerates drug development, reduces R&D costs, improves success rates.

---

## GLP-1 dominance

| Drug | Indication | Status |
|------|------------|--------|
| Mounjaro | Diabetes | Blockbuster |
| Zepbound | Obesity | Fastest launch ever |

**GLP-1 market:** $100B+ potential, Lilly and [[Novo Nordisk]] duopoly.

**US market share:** 58% (vs Novo 42%) — Lilly has taken the lead.

**Patent advantage:** Mounjaro/Zepbound (tirzepatide) has **~decade of patent life** remaining — insulated from generic threat hitting Novo in 2026.

**Zepbound vs Wegovy:** Beat Wegovy on weight loss in late 2024 study. Next-gen injectable and oral in late-stage trials.

---

## Investment case

**Bull:**
- GLP-1 market expanding (obesity epidemic)
- **Patent protection ~decade** (vs Novo losing patents 2026)
- 58% US GLP-1 share (gaining)
- Pipeline depth (oncology, Alzheimer's)
- AI-powered R&D efficiency
- Pricing power in US

**Bear:**
- Valuation stretched
- GLP-1 competition intensifying
- Medicare negotiation risk
- Manufacturing capacity constraints

---


![[lly-employees-chart.png]]
*Headcount: 50,000 (2025) — up 6.4% YoY*

## Related

- [[Agentic AI]] — drug discovery applications
- [[Novo Nordisk]] — GLP-1 competitor (losing patent protection)

*Updated 2026-02-04 (Q4 2025 earnings)*
